Armata Pharmaceuticals ARMP

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    -$0.08 (-3.67%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Armata Pharmaceuticals (ARMP)
    Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $2.023

    • Market Cap

      $73.20 Million

    • Price-Earnings Ratio

      -13.49

    • Total Outstanding Shares

      36.18 Million Shares

    • Total Employees

      75

    • Dividend

      No dividend

    • IPO Date

      May 27, 1994

    • SIC Description

      Biological Products, (no Disgnostic Substances)

    • Primary Exchange

      American Stock Exchange

    • Type

      Common Stock

    • Headquarters

      5005 mcconnell ave, Los angeles, CA, 90066

    • Homepage

      https://www.armatapharma.com

    Historical Stock Splits

    If you bought 1 share of ARMP before July 7, 2011, you'd have 10 shares today.
    Execution DateSplit Amount
    April 25, 20171-for-10 (Reverse Split)
    July 7, 2011100-for-1

    Cash Flow Statement

    July 1, 2024 to September 30, 2024
    MetricValue
    Net Cash Flow From Operating Activities$-8.86 Million
    Net Cash Flow From Operating Activities, Continuing$-8.86 Million
    Net Cash Flow From Investing Activities$-340,000
    Net Cash Flow From Financing Activities, Continuing$-61,000
    Net Cash Flow From Investing Activities, Continuing$-340,000
    Net Cash Flow From Financing Activities$-61,000

    Income Statement

    July 1, 2024 to September 30, 2024
    MetricValue
    Income/Loss From Continuing Operations Before Tax$-5.48 Million
    Costs And Expenses$12.73 Million
    Benefits Costs and Expenses$8.45 Million
    Income/Loss From Continuing Operations After Tax$-5.48 Million
    Net Income/Loss Available To Common Stockholders, Basic$-5.48 Million
    Operating Income/Loss$-9.76 Million

    Comprehensive Income

    July 1, 2024 to September 30, 2024
    MetricValue
    Comprehensive Income/Loss Attributable To Parent$-5.48 Million
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
    Other Comprehensive Income/Loss$0
    Comprehensive Income/Loss$-5.48 Million

    Balance Sheet

    July 1, 2024 to September 30, 2024
    MetricValue
    Other Non-current Assets$51.98 Million
    Noncurrent Assets$75.85 Million
    Accounts Payable$1.81 Million
    Equity Attributable To Noncontrolling Interest$0
    Noncurrent Liabilities$31.01 Million
    Other Current Liabilities$116.39 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about ARMP from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      â“’ 2025 Financhle. All Rights Reserved.